Home >
GLP-1 Finished Products >
China Tirzepatide Lyophilized High Purity 99% Peptide Powder 60mg per vial for diabetes and weight loss Manufacturer, Manufacturers
1 / 1
China Tirzepatide Lyophilized High Purity 99% Peptide Powder 60mg per vial for diabetes and weight loss Manufacturer, Manufacturers
Tirzepatide (LY3298176) is the first dual-acting agonist that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It received U.S. FDA approval in May 2022 for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise. This product is supplied as a 60mg lyophilized (freeze-dried) sterile powder in vials, which must be reconstituted with bacteriostatic water prior to administration. Compared with single GLP-1 receptor agonists such as semaglutide or dulaglutide, tirzepatide demonstrates superior efficacy in improving blood glucose regulation, enhancing insulin sensitivity, and supporting significant weight loss. These benefits are attributed to its dual-receptor synergistic mechanism of action.
Product Specifications
Name
Tirzepatide Injection Powder
Purity
99%
Appearance
White Lyophilized Powder
Administration
Subcutaneous Injection
Size
10mg, 15mg, 20mg, 30mg, 60mg
Water
≤ 3.0%
Benefits
Treating Diabetes, Weight Loss
Key Benefits
Glycemic Control
Stimulates insulin secretion in a glucose-dependent manner
Mimics the combined metabolic effects of both GIP and GLP-1
Weight Management
Promotes satiety and reduces caloric intake
Demonstrated substantial and sustained weight loss in clinical studies
Cardiovascular Health
Preliminary data indicate potential cardiovascular risk reduction in patients with T2DM
Usage and Dosage
Tirzepatide lyophilized powder (60 mg) should be reconstituted with bacteriostatic water before use. Administration is by subcutaneous injection, typically once weekly on the same day each week.
Tirzepatide 60 mg lyophilized powder represents a next-generation therapeutic advancement, combining powerful glycemic control with remarkable weight loss efficacy and potential cardiovascular protection. With a gradual titration schedule (2.5 mg → up to 60 mg), it allows enhanced tolerability and flexibility for individualized treatment. Its once-weekly administration improves adherence, making it an innovative and effective option for the management of type 2 diabetes and obesity in advanced clinical and research settings.
Frequently Asked Questions (FAQ)
What is Tirzepatide Lyophilized Powder and how does it work?
Tirzepatide (LY3298176) is a dual-acting GIP and GLP-1 receptor agonist. It works by mimicking the combined metabolic effects of both hormones to stimulate glucose-dependent insulin secretion, lower glucagon levels, enhance insulin sensitivity, and promote satiety.
How is Tirzepatide 60 mg administered?
It is supplied as a freeze-dried sterile powder that must be reconstituted with bacteriostatic water prior to use. It is administered via subcutaneous injection once weekly on the same day each week.
What is the recommended starting dose and titration schedule?
The starting dose for both Type 2 Diabetes and Weight Management is 2.5 mg once weekly. The dosage is gradually escalated every 4 weeks or based on tolerance (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg → 20 mg → 30 mg → 45 mg → up to 60 mg).
How does Tirzepatide compare to single GLP-1 receptor agonists like semaglutide?
Due to its dual GIP and GLP-1 receptor synergistic mechanism of action, Tirzepatide demonstrates superior efficacy in blood glucose regulation, insulin sensitivity improvement, and weight loss compared to single GLP-1 agonists like semaglutide or dulaglutide.
What are the potential adverse reactions associated with Tirzepatide?
Common adverse reactions include gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal discomfort), injection site reactions (redness, itching, pain), low risk of hypoglycemia (unless combined with other antidiabetics), and rarely pancreatitis or renal effects requiring monitoring.
What is the half-life of Tirzepatide?
Tirzepatide has an elimination half-life of approximately 1 week, which supports a convenient once-weekly dosing schedule.
